BARROW HANLEY GLOBAL SHARE ACTIVE ETF

ASX code: GLOB

May 2025

FUND FACTS

Investment objective: Aims to provide investors with long-term capital growth through investment in quality global shares.

FUND BENEFITS


Provides investors with the potential for capital growth through a portfolio of global companies using Barrow Hanley's experienced investment team and disciplined investment process.

FUND RISKS

All investments carry risk and different strategies may carry different levels of risk. The relevant product disclosure statement or offer document for a fund should be considered before deciding whether to acquire or hold units in that fund. Your financial adviser can assist you in determining whether a fund is suited to your financial needs.

Benchmark:	MSCI World Net Total Return Index (\$A)	
Inception date of strategy:	August 2014	
ASX commencement date:	06 June 2022	
Distribution Frequency:	Half-Yearly	
Management Fee:	0.99%*	
Investment style:	Active, fundamental, bottom-up, value	
Suggested minimum investr	ment period: Seven years or longer	

PORTFOLIO SECTORS




TOP 5 STOCK HOLDINGS

	% of Portfolio
Bank of Nova Scotia	3.0%
Sanofi SA	3.0%
Merck & Co., Inc.	2.9%
Rheinmetall AG	2.8%
BAE Systems plc	2.5%

*Information on management costs is set out in the relevant PDS

PORTFOLIO REGIONS



NET PERFORMANCE - periods ending 31 May 2025

Fund	Benchmark	Excess
2.79	5.31	-2.52
0.33	-1.34	+1.67
15.63	17.52	-1.89
16.00	19.52	-3.52
-	-	-
14.42	17.72	-3.30
	2.79 0.33 15.63 16.00 -	2.79 5.31 0.33 -1.34 15.63 17.52 16.00 19.52

Past performance is not indicative of future performance. Returns may differ due to different tax treatments.



MARKET COMMENTARY

The month of May continued with the trend of investors observing significant and shifting economic data, geopolitical headlines, and policy uncertainty that is starting to look like the norm for 2025. The rapid news flow regarding U.S. tariffs were met with more muted market reactions than April as investors are adjusting to some uncertainty. Even with the tariffs as a backdrop, global markets rallied with the U.S. leading other developed regions. Additionally, growth continued to gain momentum from April and outperformed value, reversing the trend observed in the first quarter, erasing most of the large relative losses from the first three months. Another early year trend that took a pause was developed and emerging markets outperforming U.S. equities due to the fact that the U.S. has a higher weight in growth sectors like Information Technology, although all major regions were up during the month. The big news in North America was not economic data, but the continued ramifications of tariffs on the economies of the U.S., Canada, and Mexico. U.S. markets experienced volatility in May but ultimately posted gains as the S&P 500 Index recovered above its pre-tariff announcement level by early May. Markets were buoyed by the announcement of a 90-day trade agreement with China that significantly reduced tariffs on both sides, easing recession fears, that has since all but fallen apart over rare earth mineral disputes already disrupting the automotive market. As we have seen numerous times over the past two years, a growth month dampened market breadth with the three growthiest sectors with mega-cap champions – Consumer Discretionary (i.e., Amazon), Information Technology (i.e., Microsoft and NVIDIA), and Communication Services (i.e., Alphabet and Meta)– all outperformed the index.

PORTFOLIO COMMENTARY

In this market environment, the Barrow Hanley Global Value Strategy underperformed the MSCI World Index in May, a small giveback of the gains from the first quarter, while outpacing the value index. The primary driver of underperformance was sector allocation impact with underweights to the Information Technology and Communications Services sectors, along with an overweight to Real Estate, explain a significant portion of the underperformance. Regionally, allocation impacts were modestly negative due to an overallocation to continental Europe and an underweight to the U.S.

Rheinmetall AG positively contributed to relative performance during May, continuing an outperformance trend for European defense companies. Rheinmetall reported quarterly results during the month, demonstrating strong execution with group sales rising 46% year-over-year to ϵ 2.305 billion, driven by a 73% surge in defense sales to ϵ 1.795 billion. The company's backlog grew by 56% year-over year to over ϵ 62 billion. Rheinmetall also announced another joint venture, this time with Lockheed, to produce missiles in Europe. The company continues to deliver results against a favorable geopolitical backdrop for European defense companies.

Carnival Corporation positively contributed to relative returns in May as it recovered from fears earlier in the year surrounding the macroeconomic environment. The company executed on a strategic financial initiative during the month by completing a \$1 billion private offering of 5.875% senior unsecured notes, which it used to redeem \$993 million of outstanding 7.625% notes due in 2026. This saves the company \$20 million per year in interest costs. Coupled with sustained lower oil prices, Carnival outperformed during the month.

Merck & Co., Inc. detracted from relative performance during the month as it navigated a complex landscape marked by regulatory headwinds and market volatility during the period. U.S. policy developments, including proposed drug pricing reforms by HHS and CMS, pose potential risks to Merck's pricing strategy and long-term margins, particularly for flagship therapies like Keytruda. The company also faces operational challenges, such as the suspension of GARDASIL shipments to China and the looming threat of biosimilar competition for Keytruda by late 2028. Despite these pressures, Merck reported meaningful clinical progress, including a successful Phase 3 trial in ovarian cancer and the launch of another in esophageal carcinoma. These advancements underscore Merck's continued investment in innovation as it prepares for a more competitive and regulated market environment.

Sanofi SA detracted from relative performance during the month as it experienced a mix of setbacks and strategic developments during the period. A key pipeline candidate failed to meet expectations in one of two late-stage trials for a respiratory condition, leaving its future uncertain pending further data and regulatory discussions. In parallel, Sanofi is preparing for a major product launch in respiratory care and made a large acquisition of Blueprint Medicine for \$9B to strengthen its immunology and rare disease portfolio. Given the elongated nature of pipeline opportunities and a large acquisition, we are closely monitoring the company.

OUTLOOK

Global political shifts remain a key market driver, with tariffs now front and centre. Yet their long-term impact is unclear, as political ideology often collides with practical realities. Unlike past market selloffs, volatility here stems from unpredictable policy shifts such as President Trump's 90-day tariff pause - which can reverse sentiment overnight. Markets still expect rate cuts (excluding near-term U.S. policy), but the pace and extent remain uncertain amid ongoing political developments. The Fed has paused easing, balancing strong economic data with labour market resilience. Key U.S. watchpoints include tariffs, employment, CAPEX, global influence efforts, and broader trade dynamics as the Fed stays on hold. Geopolitical risks - from Ukraine to the Middle East, and recent elections in major regions - add to volatility. Until greater clarity emerges on these fronts, we expect markets to remain in a reactive and unsettled pattern.

This publication has been prepared by Perpetual Investment Management Limited ABN 18 000 866 535 AFSL 234426 (Perpetual), as the issuer of units in the Barrow Hanley Global Share Fund (Managed Fund) (ASX: GLOB) (ETMF). It is general information only and is not intended to provide you with financial advice or take into account your objectives, financial situation or needs. You should consider with a financial adviser whether the information is suitable for your circumstances. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. The product disclosure statement for the ETMF, issued by Perpetual, should be considered before deciding whether to acquire or hold units in the ETMF. The ETMF's PDS and Target Market Determination can be obtained by calling 1800 022 033 or visiting our website www.perpetual.com.au. Investment returns, net of management costs have been calculated on the growth of Net Asset Value (NAV) after taking into account all operating expenses (including management costs) and assuming

Investment returns, net of management costs have been calculated on the growth of Net Asset Value (NAV) after taking into account all operating expenses (including management costs) and assuming reinvestment of distributions on the ex-date. Distribution return has been calculated based on the ETMF's investment portfolio return less the growth of NAV. No allowance has been made for taxation. Future returns may bear no relationship to the historical information displayed. The returns shown represent past returns only and are not indicative of future returns of an ETMF. Returns on an ETMF can be particularly volatile in the short term and in some periods may be negative. No company in the Perpetual Group (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of the ETMF or the returns of an investor's capital.



MORE INFORMATION

Investor Services 1800 635 323 Email perpetualetmf@cm.mpms.mufg.com www.perpetual.com.au